Definition & Core Concept

Heart failure (HF) is a complex, progressive clinical syndrome characterized by the inability of the heart to pump sufficient blood to meet the metabolic demands of the body, or doing so only at the expense of elevated ventricular filling pressures. The pathophysiological continuum of HF is driven by an initial myocardial insult—such as ischemic heart disease, long-standing hypertension, or cardiotoxin exposure—that triggers compensatory neurohormonal activation. Primary pathways include the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system, which initially maintain cardiac output but ultimately drive deleterious ventricular remodeling, interstitial fibrosis, and progressive structural decline.

The epidemiological burden of HF is immense, with projections indicating that nearly 3% of the United States population will be diagnosed with the condition by 2030, representing a massive demographic and economic challenge.

Pathophysiology (Rule of 3)

HF pathophysiology follows a cascade of three primary mechanisms:

1. Initial Myocardial Insult: Ischemic heart disease (most common), hypertension, valvular disease, cardiotoxins (chemotherapy, alcohol), or genetic cardiomyopathies.
2. Neurohormonal Activation: Compensatory activation of the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system. Initially maintains cardiac output but ultimately drives:
• Ventricular remodeling
• Interstitial fibrosis
• Progressive structural decline
3. Progressive Decline: Increased wall stress → further neurohormonal activation → worsening LV dysfunction → clinical decompensation.

Clinical Presentation

The clinical presentation of HF varies significantly based on whether the patient presents with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF).

Classic Signs and Symptoms:

• Exertional dyspnea (earliest symptom)
• Orthopnea (dyspnea when lying flat)
• Paroxysmal nocturnal dyspnea (waking at night gasping for air)
• Fatigue and exercise intolerance
• Edema (lower extremity, sacral, scrotal)
• Jugular venous distention (JVD)
• S3 gallop (indicates elevated filling pressures)
• Pulmonary crackles on auscultation
• Hepatomegaly and ascites (right-sided failure)

NYHA Functional Classification:

• Class I: No limitation of physical activity
• Class II: Slight limitation, comfortable at rest, symptoms with ordinary activity
• Class III: Marked limitation, comfortable at rest, symptoms with less-than-ordinary activity
• Class IV: Unable to carry out any physical activity without discomfort, symptoms at rest

Diagnostic Workup

Initial Evaluation:

• ECG: Evaluate for ischemia, arrhythmias, LV hypertrophy
• Chest X-ray: Cardiomegaly, pulmonary congestion, pleural effusions
• Biomarkers: BNP > 100 pg/mL or NT-proBNP > 300 pg/mL suggests HF (cutoffs adjust for age and renal function)

Comprehensive Laboratory Assessment:

• Complete blood count (CBC)
• Comprehensive metabolic panel (CMP) – assess electrolytes and renal function
• Lipid profile
• Iron studies (ferritin, transferrin saturation)
• Thyroid-stimulating hormone (TSH)

Advanced Imaging:

• Transthoracic echocardiogram (TTE): Gold standard – assesses LVEF, chamber sizes, valvular function, diastolic function
• Coronary angiography: If ischemic heart disease is suspected
• Cardiac MRI: For infiltrative disease, pericardial disease, or when echocardiographic windows are poor

Staging Classification:

Complications & Prognosis

Major Complications:

• Acute decompensated HF: Exacerbations requiring hospitalization
• Cardiorenal syndrome: Worsening renal function due to reduced cardiac output
• Hepatic congestion: Elevated liver enzymes, jaundice, ascites
• Malignant arrhythmias: Ventricular tachycardia, ventricular fibrillation
• Thromboembolism: Stroke, pulmonary embolism
• Cardiac cachexia: Severe weight loss and muscle wasting in advanced HF

Prognostic Indicators:

• BNP/NT-proBNP levels (higher levels correlate with worse prognosis)
• NYHA class (worse with higher class)
• LVEF (lower EF = worse prognosis)
• Comorbidities (diabetes, CKD, COPD)
• Hospitalization within 6 months (high risk of readmission and mortality)

Annual mortality: ~20-30% in symptomatic HF, up to 50% in advanced HF

Admission vs. ICU Criteria

Indications for Admission:

• New-onset HF with hemodynamic compromise
• Acute decompensated HF requiring intravenous therapy
• Significant electrolyte or metabolic abnormalities
• Need for invasive monitoring (pulmonary artery catheter)
• Unstable arrhythmias

ICU Admission Criteria:

• Cardiogenic shock (systolic BP <90 mmHg despite adequate volume resuscitation)
• Respiratory failure requiring mechanical ventilation
• Need for vasopressor or inotropic support (dobutamine, milrinone, norepinephrine)
• Acute coronary syndrome requiring urgent revascularization
• Malignant arrhythmias
• Post-cardiac arrest
• Need for mechanical circulatory support (IABP, LVAD)

Discharge & Outpatient Follow-up

• Medication optimization: Titrate GDMT to target doses within 2-4 weeks post-discharge
• Follow-up: Cardiology visit within 7 days of discharge
• Echocardiogram: Repeat 3-6 months after optimization
• Daily weights: Instruct patient to monitor daily weight and report >2-3 lb increase in 24 hours
• Dietary: 2 g sodium restriction, daily fluid restriction (1.5-2 L/day if recommended)
• Exercise: Cardiac rehabilitation program
• Immunizations: Influenza, pneumococcal, COVID-19, RSV (if eligible)

Literature & Guidelines

Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063.

McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726.

Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation. 2017;136(6):e137-e161.